Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
第一作者:
Fabio,Pace
第一单位:
Department and Chair of Gastroenterology, University of Milan, Italy.
作者:
医学主题词
2-吡啶甲基亚硫酰苯咪唑类(2-Pyridinylmethylsulfinylbenzimidazoles);成年人(Adult);人体质量指数(Body Mass Index);双盲法(Double-Blind Method);食管炎, 消化性(Esophagitis, Peptic);女(雌)性(Female);胃食管反流(Gastroesophageal Reflux);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肥胖症(Obesity);奥美拉唑(Omeprazole);超重(Overweight);质子泵抑制剂(Proton Pump Inhibitors);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome);伤口愈合(Wound Healing)
DOI
10.1097/MEG.0b013e32834991b7
PMID
21900784
发布时间
2013-11-21
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



